SXLV:SW:SW-SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc) (USD)

ETF | Others |

Last Closing

USD 42.295

Change

0.00 (0.00)%

Market Cap

N/A

Volume

323.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-04 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

+0.05 (+0.39%)

USD 1,244,681.59B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

+0.08 (+0.37%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

+0.22 (+0.83%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

+0.12 (+0.43%)

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

+42.00 (+0.53%)

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

-23.00 (-0.43%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

-12.80 (-0.77%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

-26.00 (-1.14%)

USD 134,034.85B
SPICHA:SW UBS ETF (CH) – SPI® (CHF) A..

+0.43 (+0.58%)

USD 131,872.43B
SPMCHA:SW UBS ETF (CH) – SPI® Mid (CH..

+0.88 (+0.79%)

USD 130,595.12B

ETFs Containing SXLV:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.40% 83% B 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.40% 83% B 79% B-
Trailing 12 Months  
Capital Gain 0.89% 16% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.89% 13% F 18% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.16% 58% F 59% D-
Dividend Return 6.16% 58% F 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.29% 59% D- 63% D
Risk Adjusted Return 84.50% 66% D+ 70% C-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike